Results 311 to 320 of about 281,052 (341)

Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel

Gynecologic Oncology, 2003
Although the combination of paclitaxel and carboplatin has a better therapeutic index than the combination of paclitaxel and cisplatin, peripheral neuropathy often occurs and remains the most chronic toxicity of this therapy.Six patients with ovarian or peritoneal carcinoma who developed grade 2 peripheral neuropathy during chemotherapy with paclitaxel
Peter G. Rose, Peter G. Rose, Peter G. Rose, Mary Smrekar, Mary Smrekar   +4 more
openaire   +3 more sources

Paclitaxel

2009
Publisher Summary This chapter introduces paclitaxel and describes its prepration methods, physical properties, analysis methods, stability, pharmacokinetics, and metabolism. Paclitaxel is an antineoplastic agent that is highly effective against ovarian and breast cancer.
Saurabh Jauhari, Alekha K. Dash, Somnath Singh   +2 more
openaire   +3 more sources

iRGD‐paclitaxel conjugate nanoparticles for targeted paclitaxel delivery

Drug Development Research, 2019
AbstractPaclitaxel (PTX) is a chemotherapeutic agent which shows antitumor activities against a broad spectrum of cancers. Yet, the current formulation of PTX used in clinic may cause a number of adverse reactions, which significantly limit its application.
Xiangjian Xu, Defeng Xu, Zihan Zhen, Chao Lai, Huan Zhou, Huan Zhou, Hang Hu, Bin Wang   +7 more
openaire   +3 more sources

Alternative formulations of paclitaxel

Cancer Treatment Reviews, 1997
Paclitaxel, a novel antitumour agent, is active clinically against advanced ovarian and breast cancer and under investigation for various other cancers. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water.
J. M. Meerum Terwogt, Bastiaan Nuijen, Jos H. Beijnen, Jos H. Beijnen, W.W. ten Bokkel Huinink   +4 more
openaire   +4 more sources

Metabolism of paclitaxel in mice

Anti-Cancer Drugs, 2003
Previous mass balance studies in humans and mice have shown that the fecal and urinary recovery of paclitaxel and known metabolites (3' -hydroxypaclitaxel, 6alpha-hydroxypaclitaxel and 3',6alpha-dihydroxypaclitaxel) was not complete. Obviously this discrepancy is caused by the existence of other yet unknown metabolites.
Ingrid A M Oomen, Michel J.X. Hillebrand, Jan H.M. Schellens, Jos H. Beijnen, Olaf van Tellingen, Heleen A. Bardelmeijer   +5 more
openaire   +4 more sources

Docetaxel versus paclitaxel and “paclitaxel” versus paclitaxel: The optional therapy in breast cancer

Journal of Clinical Oncology, 2006
10758 Background: For the past fifteen years many clinical trials have demonstrated that paclitaxel therapy could generate 30% to 60% response rate in patients with breast cancer. Recent clinical trials indicated that when used as control, paclitaxel therapy only produced 20% response rate in patients with breast cancer.
G. Sulemanjee, T. L. Cao, S. Ristzert
openaire   +2 more sources

Paclitaxel in cancer therapy

Expert Opinion on Pharmacotherapy, 2002
The last decade witnessed the introduction of exciting new chemotherapeutic agents. Among these, paclitaxel emerged as one of the most powerful compounds. Paclitaxel promotes the polymerisation of tubulin, thereby causing cell death by disrupting the normal microtubule dynamics required for cell division and vital interphase processes.
Maurie Markman, Tarek Mekhail
openaire   +3 more sources

Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel.

International Journal of Oncology, 1998
Our study was designed to evaluate the pharmacokinetics, tissue distribution, toxicity and therapeutic efficacy of liposome-encapsulated paclitaxel (LET) in comparison to conventional paclitaxel. In normal mice, LET was much less toxic than the conventional drug. A dose of 32.5 mg/kg of conventional paclitaxel administered i.v.
Prafulla C. Gokhale, K E Briggs, A Cabanes, J A Treat, A Rahman   +4 more
openaire   +2 more sources

Paclitaxel and its formulations

International Journal of Pharmaceutics, 2002
Paclitaxel (Taxol) is a promising anti-tumor agent with poor water solubility. It is effective for various cancers especially ovarian and breast cancer. Intravenous administration of a current formulation in a non-aqueous vehicle containing Cremophor EL may cause allergic reactions and precipitation on aqueous dilution. Moreover, the extensive clinical
Alka Garg, Anil K. Singla, Deepika Aggarwal   +2 more
openaire   +3 more sources

Liposomal paclitaxel formulations

Journal of Controlled Release, 2012
Over the past three decades, taxanes represent one of the most important new classes of drugs approved in oncology. Paclitaxel (PTX), the prototype of this class, is an anti-cancer drug approved for the treatment of breast and ovarian cancer. However, notwithstanding a suitable premedication, present-day chemotherapy employing a commercial preparation ...
Jaroslav Turánek, Štěpán Koudelka
openaire   +3 more sources